encapsulated cell therapy

encapsulated cell therapy

Therapeutics The enclosing of cells capable of producing a desired substance, in a semipermeable nonimmunogenic sheath, to restore a lost function
References in periodicals archive ?
announced today the first patient has been enrolled in the multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of recurrent subfoveal choroidal neovascularization secondary to age related macular degeneration (wet AMD).
And Thomas Chang's laboratory at McGill University pioneered encapsulated cell therapy for liver failure and as an artificial red blood cell.
We are pleased the encapsulated cell therapy being developed is being recognized by the scientific and medical community," said Dr.
Food and Drug Administration (FDA) has accepted and communicated Neurotech's ability to proceed with its Investigational New Drug (IND) application to conduct a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of recurrent subfoveal choroidal neovascularization secondary to age related macular degeneration (wet AMD).
NT-501 is designed to continually deliver a therapeutic dose of CNTF directly to the back of the eye in a controlled, continuous manner by means of the Company's proprietary Encapsulated Cell Therapy (ECT) platform.
Biotech Veteran Will Lead Clinical Development Efforts of Encapsulated Cell Therapy in Ophthalmology
NT-501 is designed to continually deliver a therapeutic dose of CNTF into the back of the eye in a controlled, continuous basis by means of the Company's proprietary Encapsulated Cell Therapy (ECT) platform.
Developing an Encapsulated Cell Therapy for Diabetes: The ViaCyte Story
a leading regenerative medicine company, has for the first time ever implanted a person with type 1 diabetes (T1D) with an experimental encapsulated cell therapy product candidate, called VC-01(TM), which is being developed for the treatment of T1D.
a leading regenerative medicine company, jointly announced that JDRF is providing additional milestone-based funding for the continued development of ViaCyte's VC-01(TM) encapsulated cell therapy product candidate for the treatment of T1D.
We also continue to have significant financial obligations with regard to our former encapsulated cell therapy facilities in Rhode Island.
has acquired all remaining co-owned rights to patents related to encapsulated cell therapy.